NCT03706573: Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

NCT03706573
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K
Breast Cancer Tissue: 
Recruitment Status: Available

Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: 
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03706573

Comments are closed.

Up ↑